The Relative Strength (RS) Rating for Dynavax Technologies stock climbed into a new percentile Monday, with an increase from 79 to 84.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's proprietary rating identifies share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Dynavax Technologies Stock A Buy?
Dynavax Technologies stock broke out of a cup with handle with a 14.48 entry. The biotech stock is still trading within its buying range.
The biotech company reported negative growth for both sales and earnings last quarter.
Dynavax Technologies stock earns the No. 121 rank among its peers in the Medical-Biomed/Biotech industry group. Arcturus Therapeutics and Kiniksa Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
